DK1492503T3 - Stabiliseret, naturlig cannabinoidformulering - Google Patents

Stabiliseret, naturlig cannabinoidformulering

Info

Publication number
DK1492503T3
DK1492503T3 DK03730170T DK03730170T DK1492503T3 DK 1492503 T3 DK1492503 T3 DK 1492503T3 DK 03730170 T DK03730170 T DK 03730170T DK 03730170 T DK03730170 T DK 03730170T DK 1492503 T3 DK1492503 T3 DK 1492503T3
Authority
DK
Denmark
Prior art keywords
sugar
natural cannabinoid
mixture
glass
drying
Prior art date
Application number
DK03730170T
Other languages
Danish (da)
English (en)
Inventor
Anko C Eissens
Drooge Dirk J Van
Wouter L J Hinrichs
Henderik W Frijlink
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of DK1492503T3 publication Critical patent/DK1492503T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03730170T 2002-04-03 2003-04-02 Stabiliseret, naturlig cannabinoidformulering DK1492503T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36961302P 2002-04-03 2002-04-03
EP02076339 2002-04-04
PCT/EP2003/050087 WO2003082246A1 (en) 2002-04-03 2003-04-02 Stabilized natural cannabinoid formulation

Publications (1)

Publication Number Publication Date
DK1492503T3 true DK1492503T3 (da) 2009-03-09

Family

ID=28676390

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03730170T DK1492503T3 (da) 2002-04-03 2003-04-02 Stabiliseret, naturlig cannabinoidformulering

Country Status (17)

Country Link
EP (1) EP1492503B1 (hr)
JP (1) JP4491241B2 (hr)
CN (1) CN100592903C (hr)
AT (1) ATE413862T1 (hr)
AU (1) AU2003240759B2 (hr)
BR (1) BR0308779A (hr)
CA (1) CA2480270A1 (hr)
DE (1) DE60324668D1 (hr)
DK (1) DK1492503T3 (hr)
ES (1) ES2316759T3 (hr)
HK (1) HK1078458A1 (hr)
HR (1) HRP20040816A2 (hr)
MX (1) MXPA04009673A (hr)
NO (1) NO20044749L (hr)
PL (1) PL209134B1 (hr)
RU (1) RU2311178C2 (hr)
WO (1) WO2003082246A1 (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
NZ619857A (en) 2010-03-29 2015-05-29 Ferring Bv A fast dissolving pharmaceutical composition
KR20140061438A (ko) 2011-09-16 2014-05-21 훼링 비.브이. 속용성 약학 조성물
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
WO2017127641A1 (en) * 2016-01-20 2017-07-27 Flurry Powders Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
US20210299202A1 (en) * 2018-07-10 2021-09-30 Cardinal Advisory Limited Formulation of cannabinoid compounds
CN110200953B (zh) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
CA3128696C (en) * 2020-08-21 2023-09-26 Organigram Inc. Buccal dosage forms comprising oligosaccharides
WO2023224960A1 (en) * 2022-05-17 2023-11-23 Orcosa Inc. Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
NL1012300C2 (nl) * 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.

Also Published As

Publication number Publication date
HRP20040816A2 (en) 2005-06-30
NO20044749L (no) 2005-01-03
CN100592903C (zh) 2010-03-03
AU2003240759B2 (en) 2008-02-14
EP1492503B1 (en) 2008-11-12
CA2480270A1 (en) 2003-10-09
CN1642527A (zh) 2005-07-20
JP4491241B2 (ja) 2010-06-30
HK1078458A1 (en) 2006-03-17
PL209134B1 (pl) 2011-07-29
ES2316759T3 (es) 2009-04-16
ATE413862T1 (de) 2008-11-15
PL372921A1 (en) 2005-08-08
RU2004132190A (ru) 2005-04-20
DE60324668D1 (de) 2008-12-24
JP2005521710A (ja) 2005-07-21
BR0308779A (pt) 2004-12-28
AU2003240759A1 (en) 2003-10-13
EP1492503A1 (en) 2005-01-05
WO2003082246A1 (en) 2003-10-09
MXPA04009673A (es) 2005-01-11
RU2311178C2 (ru) 2007-11-27

Similar Documents

Publication Publication Date Title
HK1078458A1 (en) Stabilized natural cannabinoid formulation and the prepation method thereof
AU2003285820A1 (en) Formulation for fast dissolution of lipophilic compounds
TW200621310A (en) A process for preparing formulations of lypophilic active substances by spray freeze drying
EP1461347B8 (en) 2-o-(beta-d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it
WO2009107983A3 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
AR030045A1 (es) Composicion farmaceutica que contiene compuestos antibioticos de azalida , metodos para obtencion
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
ATE272331T1 (de) Stabile, durch sprühtrocknung in einen kohlenhydratsubstrat hergestellte zubereitung und verfahren zu deren herstellung
DE50214447D1 (de) Ingwer-extraktzubereitung
RU2008127860A (ru) Фармацевтический состав для содержащих серу лекарств в жидких дозированных формах
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
EP1166792A3 (en) Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use
WO2005025500A3 (en) Process for preparing water soluble diterpenes and their applications
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
EP1358883B8 (en) Re-epithelializing pharmaceutical compositions containing xanthan gum
MXPA03010860A (es) COMPOSICION TOPICA QUE COMPRENDE UN AGENTE DE UNION COSMeTICO SUSTITUIDO.
WO2002096372A3 (en) Topical composition comprising an activated, trans-structured cosmetic bonding agent
WO2002072060A3 (en) Topical composition comprising a three membered cyclic compound-based cosmetic bonding agent
WO2003045326A3 (en) Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
WO2002072056A3 (en) Topical composition comprising a diazonium salt-based cosmetic bonding agent
CA2119548A1 (en) Odorant compositions
WO2002072055A3 (en) Topical composition comprising a cyclic imidocarbonate-based cosmetic bonding agent
AR039194A1 (es) Formulacion de cannabinoides naturales estabilizados
TH70427A (th) สูตรผสมแคนนาบินอยด์ตามธรรมชาติที่ถูกทำให้เสถียรแล้ว
WO2004075834A3 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same